Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2010.0140


KRAS-targeting agents and beyond for colorectal cancer treatment

Christos S. Katsios, M.D.

Affiliation: Christos Katsios, Associate Professor of Surgery , Department of Surgery, University Hospital of Ioannina, Ioannina, TK 45110, Greece.

Tel: +2651099696



Randomized controlled trials have shown an activity of monoclonal antibodies cetuximab and panitumumab in patients with wild-type metastatic colorectal cancer. These tumor-guided drugs demonstrate aldo an efficacy in patients with wild-type BRAF status permitting a further selection of patients and potential increased effectiveness. Here I discuss these latest advances as well the limitations of these agents and the perspectives for their clinical utility in the adjuvant setting. Moreover, it is discussed the novel direction of networks-based future agents.

(Citation: Gastric & Breast Cancer 2010; 9(4): 163-169)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €33 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 19 November 2010